Many people are well aware of metrics used to measure physical health, such as cholesterol and resting heart rate. But what about brain health? How hard is that to measure?
Founded in 2012, San Francisco-based i2Dx has set out to develop a cloud-based diagnostic platform for assessing neurological disorders and monitoring brain health. Using biomarkers such as a cerebrospinal fluid (CSF) assay, the company assesses brain health with the goal of providing a personalized record for healthy patients.
This week, the company's second patent was issued. This patent teaches curating and analyzing diagnostic data to present to a physician of a patient. In one embodiment, the invention includes a profile with information regarding a diagnosis of Alzheimer's disease or early Alzheimer's disease.
In 2012, i2Dx was funded by Biomark Capital, a venture capital firm focused on global healthcare and the life sciences with $5-$10 million initial investments.
